A double blind, randomized, crossover, standard-controlled study to determine effect of Loaf Bread + GI-Ctrl on postprandial glucose level

The increasing prevalence of type 2 diabetes mellitus (T2DM) and obesity underscores the urgent need for effective dietary interventions to mitigate postprandial hyperglycemia—a key contributor to metabolic disorders. Loaf Bread + GI-Ctrl represents a novel formulation of a common dietary staple, designed to reduce postprandial glucose spikes through the incorporation of glycemic index (GI)-modulating ingredients. When combined with nutrition education, this formulation demonstrated a reduction in postprandial glucose excursions. In contrast, conventional loaf bread, characterized by a high GI, exacerbates hyperglycemia in individuals with diabetes and those who are overweight, making it a clear target for nutritional improvement.

The primary objective of this study was to evaluate the effectiveness of Loaf Bread + GI-Ctrl in reducing postprandial glycemia—measured as the incremental area under the blood glucose curve—in a free-living population. This directly supports the broader goal of improving glycemic control. Secondary outcomes included assessments of maximum glucose concentration (Cmax), time to peak glucose level (Tmax), and tolerability, offering a well-rounded evaluation of the product’s metabolic efficacy and real-world applicability. Continuous glucose monitoring (CGM) provided precise tracking of glucose fluctuations, enabling detailed insight into the glycemic response on an individual basis.

The crossover study design enhanced statistical power by minimizing inter-individual variability, while randomization and double-blinding helped to reduce potential bias. The selected study population—overweight or obese adults with T2DM, maintained on stable metformin therapy and with low physical activity levels—represents a clinically relevant group with a critical need for improved glycemic control. Carefully defined exclusion criteria minimized potential confounders, such as complex comorbidities or use of medications beyond metformin, thereby strengthening the interpretability of the intervention’s effects.

If shown to be safe and effective, the use of Loaf Bread + GI-Ctrl may offer a practical dietary strategy for managing T2DM and obesity. These findings have the potential to influence dietary guidelines, inspire innovation in the functional food sector, and support public health strategies aimed at reducing the metabolic burden associated with these widespread conditions.